Cargando…
Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA(A) receptor positive allosteric modulator
Zuranolone (SAGE-217) is a novel, synthetic, clinical stage neuroactive steroid GABA(A) receptor positive allosteric modulator designed with the pharmacokinetic properties to support oral daily dosing. In vitro, zuranolone enhanced GABA(A) receptor current at nine unique human recombinant receptor s...
Autores principales: | Althaus, Alison L., Ackley, Michael A., Belfort, Gabriel M., Gee, Steven M., Dai, Jing, Nguyen, David P., Kazdoba, Tatiana M., Modgil, Amit, Davies, Paul A., Moss, Stephen J., Salituro, Francesco G., Hoffmann, Ethan, Hammond, Rebecca S., Robichaud, Albert J., Quirk, Michael C., Doherty, James J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265595/ https://www.ncbi.nlm.nih.gov/pubmed/32976892 http://dx.doi.org/10.1016/j.neuropharm.2020.108333 |
Ejemplares similares
-
A phase 1 double‐blind, placebo‐controlled study of zuranolone (SAGE‐217) in a phase advance model of insomnia in healthy adults
por: Bullock, Amy, et al.
Publicado: (2021) -
SAGE-217, A Novel GABA(A) Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies
por: Hoffmann, Ethan, et al.
Publicado: (2019) -
Neuroactive Steroids Reverse Tonic Inhibitory Deficits in Fragile X Syndrome Mouse Model
por: Modgil, Amit, et al.
Publicado: (2019) -
Preventing Phosphorylation of the GABA(A)R β3 Subunit Compromises the Behavioral Effects of Neuroactive Steroids
por: Vien, Thuy N., et al.
Publicado: (2022) -
Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial
por: Deligiannidis, Kristina M., et al.
Publicado: (2021)